VANCOUVER, Oct. 26,
2015 /CNW/ - iCo Therapeutics Inc. ("iCo" or "the Company")
(TSX-V: ICO) (OTCQX: ICOTF) today announced that the company has
engaged Corealis Pharma Inc. ("Corealis") a contract manufacturing
organization, for analytical development, formulation optimization
and scale-up of the amphotericin B oral delivery system. The
preparation and regulatory filings for this program are expected to
be completed in 2016, with Phase 1A study data available in
2017.
"This is a significant step in the advancement of
the oral delivery platform," said Andrew
Rae, President and CEO of iCo Therapeutics. "This work
will support manufacturing for a first-in-human phase one clinical
study."
"We are very excited to be working with Corealis
on further development of Oral Amphotericin B and are optimistic in
moving this technology forward to the clinic in due course," said
Dr. Kishor Wasan, Dean of the
College of Pharmacy and Nutrition at the University of Saskatchewan and Adjunct Professor
and Distinguished University Scholar at the University of British Columbia.
iCo has also been building its intellectual
property position around the Oral Amphotericin B asset. The company
was issued composition of matter and use patents and management is
aggressively pursuing further patent issuances in multiple
jurisdictions as it moves towards the clinic.
About iCo Therapeutics
iCo
Therapeutics in-licenses and redefines existing drug candidates or
generics by employing reformulation and delivery technologies for
new or expanded use indications. The Company holds worldwide rights
to an oral drug delivery platform, with Oral Amphotericin B (Amp B)
as the initial platform candidate, utilizing a known anti-fungal
drug to treat life-threatening infectious diseases. iCo also
has worldwide ophthalmic rights to iCo-008 is a monoclonal antibody
targeting eotaxin-1. With Phase 2 clinical history,
Bertilimumab (iCo-008) is candidate for the treatment of vernal or
atopic keratoconjunctivitis and wet age-related macular
degeneration. iCo-008 is in Phase 2 clinical studies with
iCo's partner, Immune Pharmaceuticals. iCo trades on the TSX
Venture Exchange under the symbol "ICO" and the OTCQX under the
symbol "ICOTF". For more information, visit the Company website at:
www.icotherapeutics.com.
No regulatory authority has approved or
disapproved the content of this press release. Neither the TSX
Venture Exchange nor its Regulatory Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this press
release.
Forward-Looking Statements
Certain
information contained in this news release, including any
information relating to the proposed transaction (the
"Transaction") and each issuer's future financial or
operating performance may be deemed "forward-looking". These
statements relate to future events or future performance and
reflect each issuer's expectations regarding the Transaction, and
the future growth, results of operations, business prospects and
opportunities of iCo, Diagnos and the combined company. These
forward-looking statements also reflect each issuer's current
internal projections, expectations or beliefs and are based on
information currently available to iCo or Diagnos, respectively. In
some cases forward-looking information can be identified by
terminology such as "may", "will", "should", "expect", "intend",
"plan", "anticipate", "believe", "estimate", "projects",
"potential", "scheduled", "forecast", "budget" or the negative of
those terms or other comparable terminology. Assumptions upon which
such forward looking information regarding completion of the
Transaction are based include that iCo and Diagnos will be able to
satisfy the conditions to the Transaction, that the required
approvals will be obtained from the shareholders and optionholders
of each issuer, as applicable, that all third party regulatory and
governmental approvals to the Transaction will be obtained and all
other conditions to completion of the Transaction will be satisfied
or waived. Although iCo and Diagnos believe that the
forward-looking information contained in this news release is based
on reasonable assumptions, readers cannot be assured that actual
results will be consistent with such statements. Accordingly,
readers are cautioned against placing undue reliance on
forward-looking information. iCo and Diagnos expressly disclaim any
intention or obligation to update or revise any forward-looking
information, whether as a result of new information, events or
otherwise, except in accordance with applicable securities
laws.
SOURCE iCo Therapeutics Inc.
